

1 **Title Page**

2 **Title:** Polymethylation Scores for Prenatal Maternal Smoke Exposure Persist Until Age 15 and
3 Are Detected in Saliva

4 **Authors:** Freida A. Blostein¹, Jonah Fisher², John Dou¹, Lisa Schenper³, Erin B. Ware² Daniel
5 A. Notterman^{3*}, Colter Mitchell^{2*}, Kelly M. Bakulski^{1*+}

6 **Affiliations:**

7 ¹Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor,
8 Michigan, United States of America

9 ²Institute for Social Research, University of Michigan, Ann Arbor, Michigan, United States of
10 America

11 ³Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States
12 of America

13 *Co-senior authors

14 ⁺Corresponding author: bakulski@umich.edu 1415 Washington Heights, Ann Arbor, MI, 48109

15 **Abstract**

16 **Background:** Prenatal maternal smoking has negative implications for child health. DNA
17 methylation signatures can function as biomarkers of prenatal maternal smoking. However little
18 work has assessed how DNA methylation signatures of prenatal maternal smoking vary across
19 ages, ancestry groups, or tissues. In the Fragile Families and Child Wellbeing study, we tested

20 whether prenatal maternal smoking was associated with salivary polymethylation scores for
21 smoking in participants. We assessed the consistency of associations at ages 9 and 15, their
22 portability across participants from African, European, and Hispanic genetic ancestries and the
23 accuracy of exposure classification using area under the curve (AUC) from receiver operating
24 curve analyses.

25 **Results:** We created saliva polymethylation scores using coefficients from a meta-analysis of
26 prenatal maternal smoke exposure and DNA methylation in newborn cord blood. In the full
27 sample at age 9 (n=753), prenatal maternal smoke exposure was associated with a 0.52 (95%CI:
28 0.36, 0.67) standard deviation higher polymethylation score for prenatal smoke exposure. The
29 direction and magnitude of the association was consistent when stratified by genetic ancestries.
30 In the full sample at age 15 (n=746), prenatal maternal smoke exposure was associated with a
31 0.46 (95%CI: 0.3, 0.62) standard deviation higher polymethylation score for prenatal smoke
32 exposure, and the effect size was attenuated among the European and Hispanic genetic ancestry
33 samples. The polymethylation score was reasonably accurate at classifying prenatal maternal
34 smoke exposure (AUC age 9=0.77, *P* value<0.001, age 15=0.77, *P* value<0.001). The
35 polymethylation score showed higher classification accuracy than using a single *a priori* site in
36 the *AHRR* gene (cg05575921 AUC=0.74, *P* value=0.03; age 15=0.73, *P* value=0.01).

37 **Conclusions:** Prenatal maternal smoking was associated with DNA methylation signatures in
38 saliva samples, a clinically practical tissue. Polymethylation scores for prenatal maternal
39 smoking were portable across genetic ancestries and more accurate than individual DNA
40 methylation sites. DNA polymethylation scores from saliva samples could serve as robust and
41 practical clinical biomarkers of prenatal maternal smoke exposure.

42 **Keywords**

43 DNA methylation, prenatal maternal smoking, salivary biomarker, cohort

44 **Background**

45 Maternal prenatal smoking is a public health concern. Children exposed to cigarette smoking in
46 utero are more likely to have low-birth weight, negative neurodevelopmental outcomes and
47 asthma [1]. In 2018, 11% of pregnant women in the United States aged 15-44 reported any past-
48 month cigarette use [2]. Measuring prenatal maternal smoking behavior is challenging. Maternal
49 prenatal smoking is underreported due to stigma [3, 4]. The gold-standard for smoking
50 measurements, serum cotinine levels, have a half-life of nine hours in pregnant women, limiting
51 the ability for accurate detection to a short window [5]. Further, serum cotinine measures during
52 pregnancy are rarely available outside of birth cohorts, limiting clinical application as a marker
53 of prenatal exposures. Developing a portable and reliable biomarker of prenatal maternal smoke
54 exposure would have important implications for research and clinical practice.

55 In infant cord blood and placental tissues, maternal cigarette smoking during pregnancy is
56 associated with reproducible DNA methylation signatures, though this has primarily been tested
57 in European cohorts [6–8]. Prenatal maternal cigarette smoking exposure is associated with
58 postnatal DNA methylation signatures in blood from cohorts of older children and adults [9, 10].
59 Few studies have considered the persistence of the association between maternal prenatal
60 cigarette smoking and DNA methylation at different ages in the same individuals. Additionally,
61 little work has considered the portability of the association between maternal prenatal cigarette
62 smoking and DNA methylation outside of cord blood and placental tissue. DNA methylation
63 drives cell differentiation and cell type proportions differ across tissue types. Epigenetic markers

64 of prenatal maternal smoking are known to differ between cord blood and placental samples [7].
65 Cord blood and placental samples are unlikely to be available in clinical settings. While
66 peripheral blood is a more realistic clinical sample, saliva is even easier to collect. To our
67 knowledge, no study has evaluated associations between maternal prenatal cigarette smoking and
68 salivary DNA methylation.

69 Additionally, DNA methylation can vary by genetics [11–14], and DNA methylation signatures
70 of own-smoking differ across genetic ancestry groups [15–18]. Only a few studies have
71 examined associations between prenatal maternal cigarette smoking and DNA methylation in
72 non-European ancestry populations. Among 954 infants, 70% of whom had mothers identifying
73 as Black, prenatal maternal smoking was associated with cord blood DNA methylation at 38
74 CpG sites [19]. The direction of the associations between prenatal maternal cigarette smoking
75 and DNA methylation at these sites were generally similar in children of Black and non-Black
76 participants [19]. Among 572 3–5-year-old children, 186 of whom were of African or admixed
77 genetic ancestry, prenatal maternal smoking was associated with DNA methylation in peripheral
78 blood samples, but ancestry-stratified analyses were not performed [20]. Similarly, among 89
79 middle-aged women, of whom 28 reported African American or Hispanic ethnicity, prenatal
80 maternal cigarette smoking was associated with DNA methylation at 17 of 190 tested CpG sites
81 [9]. Adjusting for ancestry did not substantially affect the association between prenatal maternal
82 smoking and DNA methylation at any of the sites, although the authors note that African
83 American women had on average 2–5% higher mean DNA methylation on the absolute scale as
84 compared with White and Hispanic women at 5 *CYP1A1* CpG sites [9]. Of 148 CpG sites
85 selected based on their association with prenatal maternal smoking among primarily European
86 children, 7 CpG sites were also associated with prenatal maternal cigarette smoking in a cohort

87 of 572 Latino children [6, 21]. While prenatal maternal cigarette smoking is associated with
88 DNA methylation, the consistency of this association across genetic ancestry is understudied.
89 After association testing, an important next step is to evaluate DNA methylation as a biomarker
90 of prenatal maternal smoke exposure by comparing DNA methylation-based classification of
91 maternal smoking behavior to self-reported behavior. Biomarkers can consist of single DNA
92 methylation sites or summary measures across multiple sites [17]. One option is a
93 polymethylation score, analogous to a polygenic score. In the polymethylation score, CpG sites
94 are weighted by the strength of their association with maternal smoking from a previous,
95 independent sample and then summed to a single score [24, 25]. One such DNA methylation
96 score calculated from cord blood classified maternal smoking behavior with an area under the
97 curve (AUC) of 0.82 in a primarily European cohort [23]. Among 572 3–5-year-old children,
98 186 of whom were of African or admixed ancestry, prenatal maternal smoking behavior was
99 classified with an AUC of 0.87 [20]. Among middle-aged adults, a score calculated using DNA
100 methylation in peripheral blood samples from a single time point could even predict prenatal
101 smoke exposure (30 years previously) with an AUC of 0.72 (95% confidence interval 0.69, 0.76)
102 [10]. Ideally, a biomarker for prenatal maternal smoking would be consistent over the life course
103 and portable across genetic ancestry groups. However, the consistency of DNA methylation as a
104 biomarker for prenatal maternal smoking across age, tissue, and genetic ancestry has not been
105 evaluated in the same study.

106 DNA methylation differences hold promise as a biomarker for prenatal maternal smoking.
107 Before translation to clinical applications, we must understand how and if the signal varies
108 across age, tissue sample, and genetic ancestry. In the Fragile Families and Child Wellbeing
109 study, a diverse longitudinal birth cohort of children, we aimed to assess the potential of salivary

110 DNA methylation biomarkers for prenatal maternal cigarette smoking. We tested associations
111 between prenatal maternal smoke exposure and saliva DNA methylation, including
112 polymethylation scores for smoke exposure, individual a priori CpG sites, global DNA
113 methylation, and epigenetic clocks. We then performed age- and ancestry-stratified analyses to
114 test the hypothesis that DNA methylation could serve as a persistent and consistent biomarker of
115 prenatal maternal smoking.

116 **Results**

117 **Study sample descriptive statistics**

118 In a sample of the Fragile Families and Child Wellbeing Study, saliva DNA methylation was
119 measured on 1806 samples from 897 unique participants with the Illumina 450K array. Complete
120 data on covariates of interest was available on 1499 samples from 809 participants who were
121 included in the analysis (Figure 1). There were 690 participants with both age 9 and age 15 DNA
122 methylation samples. Excluded samples were similar to included samples, except that included
123 samples were slightly more likely to be from children of African genetic ancestry and less likely
124 to be from children of Hispanic genetic ancestry (Supplemental Table 1). In the included sample,
125 20% percent of the mothers reported any prenatal maternal smoking, 12% reported prenatal
126 alcohol use and 5% reported prenatal drug use. The mean income to poverty ratio of mothers at
127 birth was 2.2. Of the children in the analytic sample, 50% were male, 60% were of African
128 genetic ancestry, and 24% were of Hispanic genetic ancestry.

129 We calculated several summary measures of DNA methylation, including polymethylation
130 scores for smoke exposure, global DNA methylation, and epigenetic clocks. Many of the
131 methylation summary measures were correlated with each other (Supplemental Figure 1). For

132 example, as expected, the percent of estimated immune cells was perfectly inversely correlated
133 with the percent of estimate epithelial cells (Pearson $\rho=-1$; P value<0.0001). Our
134 polymethylation score for prenatal smoke exposure, which was calculated using coefficients
135 from a cell-type corrected regression, was weakly correlated with estimated cell-type proportion
136 of immune cells (Pearson $\rho=0.05$; P value=0.038).

137 We compared epigenetic measures between the age 9 and age 15 visit among the 690 individuals
138 with data from both visits (Supplemental Figure 2). The correlation across ages was strongest for
139 the polymethylation score for prenatal smoke exposure (Pearson $\rho=0.9$, P value<0.0001). Global
140 DNA methylation (0.5, P value<0.0001) and epigenetic clocks were less strongly correlated
141 across ages (Pediatric: 0.51; P value<0.0001, GRIM: 0.47; P value<0.0001) The distribution of
142 epigenetic ages shifted higher between the age 9 and age 15 visit, as expected (Supplemental
143 Figure 3). The pediatric clock more closely reflected chronological age than the GRIM clock.
144 Among age 9 samples, the mean estimated age from the pediatric clock was 9 and the mean
145 estimated age from the GRIM clock was 25. Among age 15 samples, the mean estimated age
146 from the pediatric clock was 12 and the mean estimated age from the GRIM clock was 30. The
147 distribution of estimated cell-type proportions also shifted between visits while the distribution
148 of global methylation and polymethylation scores were more consistent (Supplemental Figure 3).

149 In bivariate analyses and multivariable models, we focused on the polymethylation score for
150 prenatal smoke exposure and the single top CpG site from prior research, cg05575921 in the
151 *AHRR* gene, as hypothesized biomarkers, and used global methylation and the pediatric clock as
152 negative controls.

153 **Bivariate associations between prenatal maternal smoking and DNA methylation summary**
154 **measures**

155 Mothers who reported smoking during pregnancy had lower income to poverty ratios (1.49) than
156 those who did not (2.38). Mothers who smoked were more likely to report prenatal alcohol use
157 (30% vs 7%), prenatal drug use (18% vs 2%) and postnatal smoking (96% vs 26%) than mothers
158 who did not report prenatal maternal smoking (Table 1). Children of mothers who reported
159 smoking during pregnancy were more likely to be of European genetic ancestry (23%) than
160 children of mothers who did not (14%, P value= <0.001). Children of mothers who reported
161 smoking during pregnancy had higher prenatal maternal smoking polymethylation scores than
162 children of mothers who did not at both the age 9 (0.08 vs -0.04, P value <0.001) and age 15
163 (0.11 vs -0.01, P value <0.001) visits (Table 1, Supplemental Table 2). At age 9, children exposed
164 to prenatal maternal smoking had lower DNA methylation at cg05575921 (76.82%) than
165 children of non-smoking mothers (77.81%, P value=0.05). At age 15, children exposed to
166 prenatal smoking had lower DNA methylation at cg05575921 (76.13%) than children of non-
167 smoking mothers, although this difference was not significant (76.82% P value= 0.24).
168 Epigenetic age from the pediatric and GRIM clocks and global DNA methylation did not differ
169 between children exposed vs unexposed to prenatal maternal smoking.

170 **Multivariable associations between prenatal maternal smoking and DNA methylation**
171 **summary measures**

172 The association between prenatal maternal smoking and the polymethylation score for prenatal
173 smoke exposure was also observed in multivariable models, adjusting for base model covariates
174 of child sex, maternal income to poverty ratio at baseline, proportion of salivary immune cells,

175 sample plate from DNA methylation analysis, child age and the first two principal components
176 of genetic ancestry (Figure 3; Supplemental Table 2). At age 9, prenatal maternal smoke
177 exposure was associated with a 0.52 (95%CI: 0.36, 0.67) standard deviation higher
178 polymethylation score for prenatal smoke exposure. At age 15, prenatal maternal smoke
179 exposure was associated with a 0.46 (95%CI: 0.3, 0.62) standard deviation higher prenatal
180 smoke exposure polymethylation score for prenatal smoke exposure. A consistent association
181 was observed when stratifying by genetic ancestry. In the African genetic ancestry sample (n=
182 488). In the African genetic ancestry sample at age 9, prenatal maternal smoking was associated
183 with a 0.55 (95%CI: 0.35, 0.75) standard deviation higher polymethylation score for prenatal
184 smoke exposure. The direction and magnitude of the association was similar in the European and
185 Hispanic genetic ancestry samples at age 9, though the effect size was attenuated and no longer
186 statistically significant at age 15 (Figure 3; Supplemental Tables 2).

187 At age 9, prenatal maternal smoking was associated with 1 percent lower DNA methylation at
188 cg055975921 (95% CI: -1.66, -0.35) after adjusting for base model covariates. Similarly, at age
189 15 prenatal maternal smoking was associated with 0.8 percent lower DNA methylation at
190 cg055975921 (95%CI: (-1.58, -0.02)). Prenatal maternal smoking remained significantly
191 associated with a decrease in cg05575921 DNA methylation in the African genetic ancestry
192 sample at age 9 (-1.34 (95%CI: -2.17, -0.5)) although the association was not significant at age
193 15 (-0.97 (95%CI: -1.98, 0.04); Figure 3). In the European genetic ancestry sample, the
194 association was consistent in direction at age 9 (-0.72 (95%CI: -2.37, 0.93)) and age 15 (-1.76
195 (95%CI: -3.42, -0.1)). In the Hispanic genetic ancestry sample, the association was no longer
196 significant and not consistent in direction (Age 9: -0.04 (95%CI: -1.67, 1.59); Age 15: 0.85
197 (95%CI: -1.25, 2.95)) (Figure 3).

198 Prenatal maternal smoking was not associated with global DNA methylation or epigenetic age
199 (Figure 3).

200 **Sensitivity analyses for association testing**

201 After additionally adjusting for other prenatal exposures and postnatal smoke exposure, the
202 association between prenatal maternal smoking and the polymethylation score was robust
203 (Supplemental Figure 4). Similarly, after adjusting for other prenatal exposures and postnatal
204 smoke exposure, the direction of the association between prenatal maternal smoking and
205 cg055975921 was consistent, although no longer significant at age 15. Very few children who
206 were exposed to maternal smoking prenatally were unexposed to postnatal smoke (Supplemental
207 Figure 5). However, children exposed only to postnatal smoke did not have higher
208 polymethylation scores than children unexposed to both postnatal and prenatal smoke
209 (Supplemental Figure 5). Results were also similar when controlling for surrogate variables
210 instead of known covariates (Supplemental Figure 6; Supplemental Table 2).

211 Results from linear mixed effect models were similar to age-stratified and base covariate
212 adjusted linear models (Supplemental Table 3 & 4).

213 Results were also similar when using polymethylation scores constructed with alternative
214 regression coefficients (see Methods, Supplemental Figure 7). For our main analysis we used
215 coefficients from a regression of sustained smoking exposure and DNA methylation in newborn
216 cord blood with cell-type control. As sensitivity analyses, we used coefficients from regressions
217 of: sustained smoking exposure and DNA methylation in newborn cord blood without cell-type
218 control, sustained smoking exposure and DNA methylation in peripheral blood from older
219 children without cell-type control, and any smoking exposure and DNA methylation in newborn

220 cord blood without cell-type control [6]. The association between prenatal maternal smoking and
221 the polymethylation score using regression coefficients from newborn cord blood with cell-type
222 controls was the strongest.

223 In addition to cg055975921 in the *AHHR* gene, we tested the association of four other *a priori*
224 probe sites identified from previous meta-analyses. We replicated the association of prenatal
225 maternal smoking with these CpG sites (Supplemental Table 2, Supplemental Figure 8).

226 **Accuracy of polymethylation scores as a biomarker of prenatal maternal smoking**

227 Next, we compared the accuracy of different DNA methylation summary measures for
228 classifying prenatal maternal smoking using receiver operating curves (Figure 4A; Supplemental
229 Table 5). We estimated classification of prenatal maternal smoking when using DNA
230 methylation summary measures alone. We also estimated prenatal maternal smoking
231 classification when using DNA methylation summary measures in addition to base model
232 covariates (child sex, maternal income to poverty ratio at baseline, child age at DNA methylation
233 measurement, estimated immune cell proportion, plate from methylation processing and the first
234 two genetic principal components). When used without DNA methylation measures, these base
235 model variables had an area under the curve (AUC) of 0.73 at age 9 and 0.72 at age 15.

236 At age 9, including the polymethylation score for prenatal smoke exposure significantly
237 improved the base model covariates classification (AUC: 0.77, *P* value comparing to base
238 model<0.001). At age 15, similarly, including the polymethylation score for prenatal smoke
239 exposure significantly improved the base model covariates classification (AUC:0.77, *P*
240 value<0.001).

241 At age 9, the base model covariates with the polymethylation score for prenatal smoke exposure
242 had a larger AUC than the base model covariates with cg05575921 (AUC base model covariates
243 + cg05575921: 0.74; P value = 0.0256). At age 15, this was also true (AUC for base model
244 covariates + cg05575921 = 0.73, P value = 0.0056; Supplemental Table 6). Accurate classification
245 was not improved by including polymethylation scores from age 9 and age 15 together (Figure
246 4B).

247 **Sensitivity analyses for biomarker accuracy assessment**

248 Classification of prenatal maternal smoke exposure when using other coefficients as the weights
249 in construction of the polymethylation scores was similar to the results when using coefficients
250 from cell-type controlled regressions of sustained prenatal maternal smoking and DNA
251 methylation in cord blood (Supplemental Table 7).

252 **Discussion**

253 In the longitudinal Fragile Families and Child Wellbeing birth cohort, we observed that prenatal
254 maternal smoking was associated with several characterizations of DNA methylation in
255 children's saliva samples from ages 9 and 15. Prenatal maternal smoking was associated with
256 polymethylation scores for prenatal smoke exposure across strata of both child age and genetic
257 ancestry. Global methylation and epigenetic clocks were not associated with maternal smoking
258 exposure. Polymethylation scores for prenatal smoke exposure had reasonable accuracy for
259 classifying prenatal maternal smoking (AUC > 0.7). Classification when using polymethylation
260 scores for prenatal maternal smoke exposure was better than when using a single *a priori* CpG
261 site, cg05575921 in the *AHRR* gene.

262 Our findings are consistent with the previous literature on associations between prenatal maternal
263 smoking and DNA methylation. We replicated the top hit from a previous epigenome wide
264 association analysis [6]. Further, we found evidence of association in several additional hits from
265 epigenome wide association studies of DNA methylation in cord and peripheral blood [6, 26].
266 There are no previous studies of prenatal maternal smoking and saliva DNA methylation.
267 However, previous work has shown that the majority of CpG sites are similarly methylated in
268 blood and saliva (reviewed in [27]).

269 We advance prenatal smoking - DNA methylation literature by evaluating the persistence of the
270 association between prenatal maternal smoking and DNA methylation as children age and its
271 portability across tissue and ancestry. Polymethylation scores built using coefficients from meta-
272 analysis of cord blood DNA methylation from primarily European-ancestry newborns were still
273 associated with prenatal maternal smoking in our independent saliva samples from a diverse
274 cohort at ages 9 and 15 [6]. The portability of other risk scores, such as polygenic risk scores,
275 across genetic ancestries is a complex research area [28] and evaluating the portability of
276 epigenetic summary measures has been identified as a key area for evaluation [29]. In this case,
277 the polymethylation score for prenatal maternal smoking appears to be portable across genetic
278 ancestry groups. Effect estimates were consistent across ancestries at age 9, although Hispanic
279 and European genetic ancestry samples had lower, non-significant effect estimates at age 15. The
280 decreased precision may be the result of the reduced sample size of the Hispanic and European
281 genetic ancestry samples. The reduction in effect estimate magnitude could reflect higher
282 unreported smoking initiation in European and Hispanic ancestry teens in the United States than
283 African ancestry teens. Genetic ancestry correlates with race, and White and Latino teens have
284 much higher rates of teen smoking and earlier ages at initiation than Black children [30]. Though

285 we excluded children who reported own-smoking from our analytic sample, under-reporting of
286 own-smoking could influence DNA methylation at ages 9 and 15, creating outcome
287 misclassification. This could also explain the observed attenuation of the effect on
288 *AHRR:cg05575921* methylation by age 15 in our sample, as DNA methylation at this probe is
289 known to vary by personal cigarette smoking [22, 31].

290 Our findings are also consistent with previous work on DNA methylation as a biomarker for
291 prenatal maternal smoke exposure. Prenatal maternal smoking classification using saliva DNA
292 methylation in our sample of 9- and 15-year-olds performed comparably to classification using
293 peripheral blood from older adults (AUC 0.72) [10]. However, previous prenatal maternal smoke
294 exposure biomarkers created using LASSO regression and cord blood from newborns performed
295 better (AUCs ranging from 0.82-0.97) [20] A support vector machine approach performed on
296 and peripheral blood from 3–5-year-old children also more accurately classified prenatal
297 maternal smoke exposure (AUC=0.87) [23]. Differences in DNA methylation patterns across
298 tissues and over time may influence the performance of DNA methylation biomarkers. Different
299 methods for summarizing across multiple DNA methylation sites may also influence biomarker
300 performance. The similarity in performance between saliva DNA methylation in our study and
301 peripheral blood DNA methylation in older adults is encouraging for the use of saliva as a
302 readily accessible clinical sample.

303 Our analysis contributes to the development of an accurate methylation biomarker for prenatal
304 maternal smoking by evaluating the impact of specific methodological choices on accuracy of
305 classification. DNA methylation biomarkers may be especially susceptible to confounding by
306 subject age at methylation measurement and cell-type proportion [29]. Prenatal maternal smoke
307 exposure classification accuracy of polymethylation score was similar when using coefficients

308 from cord blood vs peripheral blood samples from older children. Classification accuracy was
309 not improved by using two time-points of methylation measurement. Classification accuracy was
310 improved when polymethylation scores used coefficients which incorporated cell-type control.
311 Our analysis therefore suggests that cell-type control when both generating (in the epigenome
312 wide association study) and applying coefficients for polymethylation scores may positively
313 influence outcome classification accuracy, although more work comparing coefficients from
314 different populations is still needed.

315 Our analysis suggests that polymethylation scores may be more accurate than using single CpG
316 sites as biomarkers. The site cg05575921 in the *AHRR* gene is a consistent marker of prenatal
317 maternal smoke exposure in meta-analyses of newborn cord blood [6]. DNA methylation at
318 cg05575291 in the *AHRR* gene can accurately classify own-smoking behavior in both blood
319 (area under the curve 0.995) and saliva (area under the curve 0.971) [22, 31]. However, salivary
320 *AHRR*:cg05575921 was not a persistent marker of prenatal maternal smoking in an analysis of
321 middle-aged adult women [10]. In our sample, salivary *AHRR*:cg05575921 methylation was less
322 accurate at predicting prenatal maternal smoke exposure than polymethylation scores. The
323 accuracy of *AHRR*:cg05575921 and other single CpG site biomarkers may be influenced by
324 time-since-exposure and new environmental exposures. Incorporating information across
325 multiple sites of DNA methylation may yield a biomarker more robust to these influences.

326 Our analysis is not without its limitations. We used maternal self-report of prenatal maternal
327 smoke exposure, as serum cotinine levels were not available. Due to social desirability bias, this
328 could result in exposure misclassification. We would expect this to bias our results towards the
329 null. In any analysis of a prenatal exposure and postnatal outcome, there is the possibility of
330 selection bias into the cohort due to live birth bias. Selection bias is also possible due to loss-to-

331 follow-up between birth and age 15. Additionally, while we controlled for postnatal secondhand
332 smoke exposure and excluded children who reported any own-smoking, we cannot exclude the
333 possibility of residual confounding in this observational cohort.

334 However, our analysis also has several strengths. We analyzed samples from a large cohort of
335 diverse participants underrepresented in genetic and epigenetic research [32, 33]. While our
336 exposure measurement of prenatal maternal smoking was self-reported, it was assessed
337 prospectively and preceded outcome measurements. We analyzed repeated measures of DNA
338 methylation with reproducible array measures conducted in a single batch. We tested
339 associations between prenatal maternal smoking and multiple DNA summary measures to
340 evaluate the specificity of the polymethylation scores. In sensitivity analyses, we adjusted for
341 other prenatal exposures and postnatal smoke exposure to examine the specificity of the
342 biomarker to nature and timing of exposure.

343 **Conclusions**

344 In a large, prospective study of diverse participants, we showed that DNA methylation in
345 children's saliva had strong associations with and reasonable classification accuracy for prenatal
346 maternal smoke exposure. Further, we demonstrated that polymethylation scores could be
347 applied as a biomarker of prenatal maternal smoke exposure across genetic ancestry groups, an
348 important consideration for the equitable biomarker development. The development and
349 application of biomarkers for prenatal maternal smoke exposure has important implications for
350 epidemiological research and clinical practice. Given the difficulty of measuring prenatal
351 maternal smoke exposure, such a biomarker could allow for confounder control in research areas
352 where such control is currently impossible. Prenatal maternal smoke exposure is prevalent and

353 has negative health consequences, thus an exposure biomarker could be used to provide support
354 and health interventions for children.

355 **Methods**

356 **Cohort**

357 The Fragile Families and Child Wellbeing Study is a birth cohort of nearly 5,000 children born
358 in 20 cities in the United States between 1998 and 2000 [34]. Participants were selected at
359 delivery using a three-stage stratified random sample design which oversampled unmarried
360 mothers by a ratio of 3:1 [34]. Participants were excluded on the following criteria: those with
361 parents who planned to place the child for adoption, those where the father was deceased, those
362 who did not speak English or Spanish well enough to be interviewed, births where the mothers or
363 babies were too ill to complete the interview, and those where the baby died before the interview
364 could take place. Children were followed longitudinally with assessments at ages 1, 3, 5, 9 and
365 15; additional follow up is ongoing. Assessments included medical record extraction, biosample
366 collection, in-home assessments, and surveys of the mother, father, primary caregiver, teacher
367 and child. At ages nine and fifteen a saliva sample was taken from the child [34]. A subsample of
368 the Fragile Families cohort was selected for saliva DNA and DNA methylation processing. This
369 subsample preferentially sampled children who had completed visits at age 9 and age 15 and
370 were from the Detroit, Toledo, and Chicago sites, as a funding supplement for these sites was
371 available.

372 **Covariates and exposure measurement**

373 Demographic and prenatal maternal substance use variables were derived from maternal self-
374 report questionnaire data at baseline (child's birth).

375 Maternal covariates included maternal income to poverty ratio at baseline, prenatal smoking,
376 prenatal maternal drug and alcohol use, and postnatal maternal or primary caregiver smoking.
377 Maternal income to poverty ratio is a constructed variable of the ratio of total household income
378 (as self-reported by the mother) to the official poverty thresholds designated by the United States
379 Census Bureau for the year preceding the interview. At baseline, mother's answered categorical
380 questions about their prenatal smoking, drug, and alcohol use. For maternal prenatal smoking,
381 mothers were asked

382 During your pregnancy, how many cigarettes did you smoke? Did you smoke...:

383 2 or more packs a day

384 1 or more but less than 2 packs per day

385 Less than 1 pack a day

386 None

387 Few participants reported smoking a pack or more a day, thus we dichotomized to any vs no
388 prenatal maternal smoking. For maternal prenatal drug and alcohol use the mothers were asked

389 During your pregnancy how often did you use drugs/drink alcohol (respectively):

390 Never

391 Less than 1 time per month

392 Several times per month

393 Several times per week

394 Every day

395 When the child was 1, 5, 9 and 15 years of age, primary caregivers responded to questions about
396 maternal and in-home smoking. To encapsulate general early childhood smoke exposure, we
397 created a binary variable for postnatal exposure at ages 1 or 5. To encapsulate recent postnatal
398 smoke exposure, we used a categorical variable for packs per day (no smoking, less than one
399 pack/day, one or more packs/day) in the month prior to the age 9 and 15 interview.

400 Child covariates included child sex, child report of personal cigarette smoking, and child genetic
401 ancestry. Mothers reported sex (male/female) of their child at baseline. At ages 9 children were
402 asked if they had ever smoked a cigarette or used tobacco (yes/no) and at age 15 they were asked
403 if they had ever smoked an entire cigarette (yes/no).

404 Child genetic ancestry was calculated. Grants R01 HD36916, R01 HD073352, and R01
405 HD076592 provided support for the collection, assay, and analysis of the genetic data in the
406 Fragile Families cohort. Principal components (PC) of child genetic ancestry were calculated
407 from genetic data using Illumina PsychChip_v1-1 with child saliva samples. Genetic ancestry
408 was assigned by comparing PC loadings to 1000 Genomes super population clusters. Samples
409 with $PC1 > 0.018$ and $PC2 > -0.0075$ were assigned to European ancestry. Samples with $PC1 < -$
410 0.005 and $PC2 > 0.007 + 0.75(PC1)$ were assigned to African ancestry. Samples with $PC1 > 0.018$
411 and $-0.055 < PC2 < 0.025$ were assigned to Hispanic ancestry [35].

412 **DNA methylation measurement**

413 Salivary samples from the children were collected at ages nine and fifteen using the
414 Oragene•DNA sample collection kit (DNA Genotek Inc., Ontario). Saliva DNA was extracted
415 manually using DNA Genotek's purification protocol using prepIT L2P. DNA was bisulfite
416 treated and cleaned using the EZ DNA Methylation kit (Zymo Research, California). Samples

417 were randomized and plated across slides by demographic characteristics. Saliva DNA
418 methylation was measured using the Illumina HumanMethylation 450k BeadArray [36] and
419 imaged using the Illumina iScan system. All samples were run in a single batch to minimize
420 technical variability.

421 DNA methylation image data were processed in R statistical software (3.5) using the minfi
422 package [37]. The red and green image pairs (n=1811) were read into R and the minfi
423 *preprocessNoob* function was used to normalize dye bias and apply background correction.
424 Further quality control was applied using the ewastools packages [38]. We dropped samples with
425 >10% of sites have detection p-value >0.01 (n=43), sex discordance between DNA methylation
426 predicted sex and recorded sex (n=20), and abnormal sex chromosome intensity (n=3). CpG sites
427 were removed if they had detection p-value >0.01 in 5% of samples (n=26,830) or were
428 identified as cross-reactive (n=27,782) (Figure 1) [39]. We used the November 2021 data freeze
429 of the Fragile Families and Child Wellbeing DNA methylation data. Relative proportions of
430 immune and epithelial cell types were estimated from DNA methylation measures using a
431 childhood saliva reference panel [40].

432 We created polymethylation scores for prenatal maternal smoke exposure. From an independent
433 meta-analysis of prenatal smoke exposure and newborn DNA methylation, we extracted the
434 regression coefficients of 6,074 CpG sites associated with prenatal maternal smoking at a false
435 discovery ratio corrected *P* value <0.05 [6]. We mean-centered the DNA methylation beta values
436 in our study, weighted them by the independent regression coefficients and took the sum. We
437 calculated polymethylation scores using regression coefficients from 4 different regressions. For
438 our main analysis we used coefficients from a regression of sustained smoking exposure and
439 DNA methylation in newborn cord blood with cell-type control. As sensitivity analyses, we used

440 sustained smoking exposure and DNA methylation in newborn cord blood without cell-type
441 control, sustained smoking exposure and DNA methylation in peripheral blood from older
442 children, any smoking exposure and DNA methylation in newborn cord blood) [6].

443 Global DNA methylation was calculated for each sample as the mean methylation value of each
444 sample across the cleaned probe set. Mean DNA methylation restricted to probes in genomic
445 regions (CpG island, shore, shelf or open sea, as identified in the R package
446 IlluminaHumanMethylation450kanno.ilmn12.hg19 v 0.6.0) was also calculated.

447 Pediatric epigenetic age was calculated for each sample using the coefficients and methods
448 provided by the creators (see <https://github.com/kobor-lab/Public-Scripts>) [41]. The GRIM
449 age clock, including the smoking pack-years sub-scale, was calculated as previously described
450 [42].

451 Single *a priori* CpG sites were selected from previous large meta-analyses of prenatal maternal
452 smoking and DNA methylation in children's cord and peripheral blood samples [6, 26].

453 Surrogate variables were calculated from DNA methylation data using the function *sva* from the
454 R package *sva* version 3.38.

455 **Statistical analyses**

456 *Inclusion exclusion criteria*

457 From the 1685 samples from 882 unique individuals with quality-controlled DNA methylation
458 data, we further excluded any samples missing data on: maternal prenatal smoking (0 samples),
459 alcohol (4 samples) or other drug use (6 samples), maternal income to poverty ratio (0 samples),
460 maternal postnatal smoking data (105 samples). We also excluded samples with missing child

461 sex (0 samples), child age (0 samples) or genetic data (22 samples). Finally, if a child reported
462 ever smoking a cigarette or using tobacco age 9, we excluded all of their available samples. Age
463 15 samples from children who reported ever smoking a cigarette at age 15 were also excluded.
464 Children who were missing a response to the question at age 9 but answered that they had never
465 smoked a whole cigarette at age 15 were kept in the sample.

466 *Base model*

467 In our base model we adjusted for maternal income to poverty ratio at baseline, child sex, child
468 age, plate from DNA methylation processing, and estimated immune cell proportion estimated
469 from DNA methylation. In nonstratified models, we adjusted for the first two components of
470 genetic ancestry from principal component analysis. In ancestry-stratified models, the first two
471 principal components from principal component analysis run within each ancestry strata were
472 used. While child sex, child age, plate from DNA methylation processing and immune cell
473 proportions are not confounders (as they cannot casually affect prenatal maternal smoke
474 exposure), these variables can strongly affect DNA methylation and so were adjusted for as
475 precision variables.

476 *Receiver operator curve analysis*

477 To evaluate the accuracy of the DNA methylation summary measures as biomarkers of prenatal
478 maternal smoking, we used a receiver operating curve. First, we regressed exposure to prenatal
479 maternal smoking (outcome) against the DNA methylation summary measures in individual
480 logistic regressions, while adjusting for the base model variables listed above. Next, we
481 calculated receiver operating curves (ROC) and area under the curves (AUCs) using the function

482 roc from the R library pROC version 1.18.0. We compared ROC curves and AUC using the
483 Delong method and the function roc.test from the R library pROC version 1.18.0.

484 *Sensitivity analyses*

485 In sensitivity analyses we performed additional adjustments: 1) models adjusting for prenatal
486 drug and alcohol use, 2) models adjusting for prenatal drug and alcohol use and postnatal
487 maternal/primary caregiver smoking, 3) models adjusting for surrogate variables calculated from
488 DNA methylation data.

489 In addition to the cross-sectional models within visit-strata, we performed a linear mixed effect
490 model with a random intercept for child.

491 Code to perform all analyses is available (www.github.com/bakulskilab)

492 **Declarations**

493 **Ethics approval and consent to participate**

494 Participants provided written informed consent for the study. The data used in this manuscript
495 were prepared by the Fragile Families and Childhood Wellbeing Study administrators following
496 approval of the manuscript proposal. These secondary data analyses were approved by the
497 University of Michigan Institutional Review Board (IRB, HUM00129826)

498 **Consent for publication**

499 Not applicable

500 **Availability of data and materials**

501 Many of the variables used in this analysis are publicly available in the Fragile Families dataset.

502 Some of the data used in this analysis, including genetic and epigenetic data, is restricted use but
503 available to researchers upon reasonable application.

504 **Competing interests**

505 The authors have no competing interests to declare.

506 **Funding**

507 This research was made possible through several grants (Fragile Families Core Data Collection:
508 R01 HD036916, R25 AG053227, genetic data processing R01 HD36916, R01 HD073352, and
509 R01 HD076592). FB was supported by the National Institutes of Health National Institute of
510 Dental and Craniofacial Research (F31 DE029992). EB was supported by (R01 AG055406, R01
511 AG067592, R01 MD011716).

512 **Authors' contributions**

513 FB performed the analysis with contributions from JD, JF, and EW. FB and KB wrote the paper
514 with all authors contributing to revisions. CM, DN and LS contributed to the design and
515 processing of the DNA methylation data subcohort. DN, CM, KM, EW, and FB all contributed
516 to the design and conception of the analytic plan. All authors reviewed and revised the
517 manuscript.

518

519 *Table 1: Bivariate associations between prenatal maternal smoke exposure and selected DNA*
 520 *methylation summary measures and important covariates among a diverse sample of 809*
 521 *children in the Fragile Families and Child Wellbeing study*

Characteristic	Age 9				Age 15			
	N	Not exposed, N = 598 ^l	Smoke exposed, N = 155 ^l	p-value ²	N	Not exposed, N = 603 ^l	Smoke exposed, N = 143 ^l	p-value
Child characteristics								
Polymethylation score for smoke exposure*	753	-0.04 (0.22)	0.08 (0.22)	<0.001	746	-0.01 (0.22)	0.11 (0.23)	<0.00
AHRR gene: percent cg05575921 methylation	753	77.8 (5.2)	76.8 (5.6)	0.047	746	77 (6)	76 (6)	0.2
Pediatric epigenetic clock (years)	753	8.98 (0.75)	8.94 (0.83)	0.6	746	11.62 (1.75)	11.59 (1.70)	0.9
Percent global DNA methylation	753	47.51 (0.74)	47.59 (0.78)	0.3	746	47.48 (0.85)	47.58 (0.83)	0.2
Immune cell proportion (saliva)	753	0.96 (0.10)	0.96 (0.08)	0.4	746	0.92 (0.15)	0.92 (0.14)	>0.9
Epithelial cell proportion (saliva)	753	0.04 (0.10)	0.04 (0.08)	0.4	746	0.08 (0.15)	0.08 (0.14)	>0.9
Ancestry categorization from child principal components of genetic data	753			0.001	746			0.001
African ancestry		355 (59%)	97 (63%)			364 (60%)	88 (62%)	
European ancestry		82 (14%)	35 (23%)			84 (14%)	34 (24%)	

Characteristic	Age 9				Age 15			
	N	Not exposed, N = 598 ¹	Smoke exposed, N = 155 ¹	p-value ²	N	Not exposed, N = 603 ¹	Smoke exposed, N = 143 ¹	p-value
Hispanic ancestry		161 (27%)	23 (15%)			155 (26%)	21 (15%)	
Child gender	753			0.8	746			0.9
Boy		300 (50%)	76 (49%)			295 (49%)	69 (48%)	
Girl		298 (50%)	79 (51%)			308 (51%)	74 (52%)	
Maternal characteristics								
Maternal prenatal alcohol use	753	44 (7.4%)	47 (30%)	<0.001	746	40 (6.6%)	42 (29%)	<0.001
Maternal prenatal any drug use	753	10 (1.7%)	26 (17%)	<0.001	746	9 (1.5%)	28 (20%)	<0.001
Maternal income to poverty threshold (at baseline)	753	2.41 (2.57)	1.52 (1.56)	<0.001	746	2.41 (2.58)	1.49 (1.57)	<0.001
Postnatal maternal smoking at ages 1 or 5	753			<0.001	746			<0.001
No maternal smoking at age 1 and 5		447 (75%)	7 (4.5%)			448 (74%)	7 (4.9%)	
Maternal smoking at age 1 or age 5		151 (25%)	148 (95%)			155 (26%)	136 (95%)	
Postnatal primary caregiver smoking in past month prior to visit	753			<0.001	746			<0.001

Characteristic	Age 9			Age 15				
	N	Not exposed, N = 598 ¹	Smoke exposed, N = 155 ¹	p-value ²	N	Not exposed, N = 603 ¹	Smoke exposed, N = 143 ¹	p-value
No smoking		476 (80%)	23 (15%)			511 (85%)	44 (31%)	
Less than pack a day		95 (16%)	85 (55%)			80 (13%)	77 (54%)	
Pack or more a day		27 (4.5%)	47 (30%)			12 (2.0%)	22 (15%)	

Mean (SD); n (%)

Welch Two Sample t-test; Pearson's Chi-squared test

Poymethylation score constructed using regression coefficients from a model of prenatal maternal smoking and DNA methylation in newborn cord blood as weights. DNA methylat eta values from Fragile Families and Child Wellbeing study were mean-centered, weighted by the regression coefficients and summed.

522

523

524

525

526

527 *Figure 1 - Selection of samples from the Fragile Families and Child Wellbeing study into*
528 *analytic subset. N represents the number of individuals at each step in the selection procedure,*
529 *M represents the number of samples. Individuals with repeated measures can have more than*
530 *one sample.*

531 *Figure 2 - Differences in selected DNA methylation summary measures by self-report of*
532 *prenatal maternal smoking among 809 children in the Fragile Families and Child Wellbeing*
533 *study at ages 9 and 15. Samples from children exposed to prenatal maternal smoke in grey,*
534 *samples from children unexposed to prenatal maternal smoke in black. From top-left, clockwise:*
535 *Polymethylation scores for prenatal maternal smoke exposure, constructed using regression*
536 *coefficients for prenatal smoke exposure predicting DNA methylation in newborn cord blood*
537 *samples, accounting for cell-type control. DNA methylation values from samples in the Fragile*
538 *Families and Child Wellbeing study were mean-centered, then multiplied by these regression*
539 *coefficients and summed. Pediatric epigenetic clock (years). AHRR gene: percent cg05575921*
540 *methylation. Percent global DNA methylation. **** P value<0.0001 *P value<0.05, ns P*
541 *value>0.05*

542 *Figure 3 - Prenatal maternal smoke exposure is consistently associated with polymethylation*
543 *scores at ages 9 and 15 and is portable across genetic ancestry groups in a sample of 809*
544 *children in the Fragile Families and Child Wellbeing study All models shown controlled for:*
545 *first two principal components of child genetic ancestry (from ancestry-stratified principal*
546 *components for ancestry stratified models), child sex, maternal income-to-poverty ratio at birth,*
547 *immune cell proportion estimated from methylation data, yes/no other maternal prenatal drug*
548 *use, yes/no maternal prenatal alcohol use, postnatal maternal smoking when child 1 or 5 years*
549 *of age, postnatal maternal/primary care give smoking packs/day in month prior to saliva sample.*
550 *Poymethylation score constructed using regression coefficients from a model of prenatal*
551 *maternal smoking and DNA methylation in newborn cord blood as weights. DNA methylation*
552 *beta values from Fragile Families and Child Wellbeing study were mean-centered, weighted by*
553 *the regression coefficients and summed. The resulting scores were z-score standardized and used*
554 *as outcomes in these models. Red dotted line denotes the null.*

555 *Figure 4 - Polymethylation scores accurately classify prenatal maternal smoke exposure at*
556 *ages 9 and 15 among 809 children in the Fragile Families and Child Wellbeing study A)*
557 *Receiver operator curve for select DNA methylation measures for predicting prenatal smoke*
558 *exposure using no other variables (light colors) or using base model variables (dark colors,*
559 *other variables included: child sex, maternal income-poverty ratio at birth, immune cell*
560 *proportion and batch of methylation data processing). B) Receiver operator curve for including*
561 *polymethylation scores individually at each visit (black & light grey) or jointly at both visits*
562 *(dark grey). Polymethylation score constructed using regression coefficients from a model of*
563 *prenatal maternal smoking and DNA methylation in newborn cord blood as weights. DNA*
564 *methylation beta values from Fragile Families and Child Wellbeing study were mean-centered,*
565 *weighted by the regression coefficients and summed. The resulting scores were z-score*
566 *standardized*

567

568 **References**

- 569 1. Banderali G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, Lassandro C, Verduci E
570 (2015) Short and long term health effects of parental tobacco smoking during pregnancy and
571 lactation: A descriptive review. *J Transl Med* 13:327
- 572 2. (2019) National survey on drug use and health 2018.
- 573 3. Kvalvik LG, Nilsen RM, Skjærven R, Vollset SE, Midttun O, Ueland PM, Haug K
574 (2012) Self-reported smoking status and plasma cotinine concentrations among pregnant women
575 in the norwegian mother and child cohort study. *Pediatr Res* 72:101–7

- 576 4. Dietz PM, Homa D, England LJ, Burley K, Tong VT, Dube SR, Bernert JT (2011)
577 Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of
578 reproductive age in the united states. *Am J Epidemiol* 173:355–9
- 579 5. Dempsey D, Jacob P 3rd, Benowitz NL (2002) Accelerated metabolism of nicotine and
580 cotinine in pregnant smokers. *J Pharmacol Exp Ther* 301:594–8
- 581 6. Joubert BR, Felix JF, Yousefi P, et al (2016) DNA methylation in newborns and maternal
582 smoking in pregnancy: Genome-wide consortium meta-analysis. *Am J Hum Genet* 98:680–696
- 583 7. Everson TM, Vives-Usano M, Seyve E, et al (2021) Placental DNA methylation
584 signatures of maternal smoking during pregnancy and potential impacts on fetal growth. *Nat*
585 *Commun* 12:5095
- 586 8. Cardenas A, Lutz SM, Everson TM, Perron P, Bouchard L, Hivert M-F (2019) Mediation
587 by Placental DNA Methylation of the Association of Prenatal Maternal Smoking and Birth
588 Weight. *American Journal of Epidemiology* 188:1878–1886
- 589 9. Tehranifar P, Wu H-C, McDonald JA, Jasmine F, Santella RM, Gurvich I, Flom JD,
590 Terry MB (2018) Maternal cigarette smoking during pregnancy and offspring DNA methylation
591 in midlife. *Epigenetics* 13:129–134
- 592 10. Richmond RC, Suderman M, Langdon R, Relton CL, Davey Smith G (2018) DNA
593 methylation as a marker for prenatal smoke exposure in adults. *Int J Epidemiol* 47:1120–1130
- 594 11. Galanter JM, Gignoux CR, Oh SS, et al (2017) Differential methylation between ethnic
595 sub-groups reflects the effect of genetic ancestry and environmental exposures. *eLife*.
596 <https://doi.org/10.7554/elife.20532>
- 597 12. Fraser HB, Lam LL, Neumann SM, Kobor MS (2012) Population-specificity of human
598 DNA methylation. *Genome Biology* 13:R8

- 599 13. Moen EL, Zhang X, Mu W, Delaney SM, Wing C, McQuade J, Myers J, Godley LA,
600 Dolan ME, Zhang W (2013) Genome-Wide Variation of Cytosine Modifications Between
601 European and African Populations and the Implications for Complex Traits. *Genetics* 194:987–
602 996
- 603 14. Rahmani E, Shenhav L, Schweiger R, et al (2017) Genome-wide methylation data mirror
604 ancestry information. *Epigenetics & Chromatin*. <https://doi.org/10.1186/s13072-016-0108-y>
- 605 15. Barcelona V, Huang Y, Brown K, Liu J, Zhao W, Yu M, Kardia SLR, Smith JA, Taylor
606 JY, Sun YV (2019) Novel DNA methylation sites associated with cigarette smoking among
607 African Americans. *Epigenetics* 14:383–391
- 608 16. Sun YV, Smith AK, Conneely KN, et al (2013) Epigenomic association analysis
609 identifies smoking-related DNA methylation sites in African Americans. *Human Genetics*
610 132:1027–1037
- 611 17. Philibert RA, Beach SRH, Lei M-K, Brody GH (2013) Changes in DNA methylation at
612 the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. *Clinical*
613 *Epigenetics*. <https://doi.org/10.1186/1868-7083-5-19>
- 614 18. Philibert RA, Beach SRH, Brody GH (2012) Demethylation of the aryl hydrocarbon
615 receptor repressor as a biomarker for nascent smokers. *Epigenetics* 7:1331–1338
- 616 19. Xu R, Hong X, Zhang B, Huang W, Hou W, Wang G, Wang X, Igusa T, Liang L, Ji H
617 (2021) DNA methylation mediates the effect of maternal smoking on offspring birthweight: a
618 birth cohort study of multi-ethnic US mothernewborn pairs. *Clinical Epigenetics*.
619 <https://doi.org/10.1186/s13148-021-01032-6>
- 620 20. Ladd-Acosta C, Shu C, Lee BK, et al (2016) Presence of an epigenetic signature of
621 prenatal cigarette smoke exposure in childhood. *Environ Res* 144:139–148

- 622 21. Neophytou AM, Oh SS, Hu D, Huntsman S, Eng C, Rodriguez-Santana JR, Kumar R,
623 Balmes JR, Eisen EA, Burchard EG (2019) In utero tobacco smoke exposure, DNA methylation,
624 and asthma in latino children. *Environmental Epidemiology* 3:
- 625 22. Philibert R, Dogan M, Beach SRH, Mills JA, Long JD (2019) AHRR methylation
626 predicts smoking status and smoking intensity in both saliva and blood DNA. *American Journal*
627 *of Medical Genetics Part B: Neuropsychiatric Genetics* 183:51–60
- 628 23. Reese SE, Zhao S, Wu MC, et al (2017) DNA methylation score as a biomarker in
629 newborns for sustained maternal smoking during pregnancy. *Environ Health Perspect* 125:760–
630 766
- 631 24. Chen J, Zang Z, Braun U, et al (2020) Association of a Reproducible Epigenetic Risk
632 Profile for Schizophrenia With Brain Methylation and Function. *JAMA Psychiatry* 77:628
- 633 25. Bakulski KM, Fisher JD, Dou JF, Gard A, Schneper L, Notterman DA, Ware EB,
634 Mitchell C (2021) Prenatal Particulate Matter Exposure Is Associated with Saliva DNA
635 Methylation at Age 15: Applying Cumulative DNA Methylation Scores as an Exposure
636 Biomarker. *Toxics* 9:262
- 637 26. Wiklund P, Karhunen V, Richmond RC, et al (2019) DNA methylation links prenatal
638 smoking exposure to later life health outcomes in offspring. *Clinical Epigenetics*.
639 <https://doi.org/10.1186/s13148-019-0683-4>
- 640 27. Langie SAS, Moisse M, Declerck K, Koppen G, Godderis L, Vanden Berghe W, Drury
641 S, De Boever P (2017) Salivary DNA Methylation Profiling: Aspects to Consider for Biomarker
642 Identification. *Basic & Clinical Pharmacology & Toxicology* 121:93–101
- 643 28. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ (2019) Clinical use of
644 current polygenic risk scores may exacerbate health disparities. *Nature Genetics* 51:584–591

- 645 29. Hüls A, Czamara D (2019) Methodological challenges in constructing DNA methylation
646 risk scores. *Epigenetics* 15:1–11
- 647 30. El-Toukhy S, Sabado M, Choi K (2016) Trends in Susceptibility to Smoking by Race and
648 Ethnicity. *Pediatrics* 138:e20161254
- 649 31. Dawes K, Andersen A, Vercande K, Papworth E, Philibert W, Beach SRH, Gibbons FX,
650 Gerrard M, Philibert R (2019) Saliva DNA Methylation Detects Nascent Smoking in
651 Adolescents. *Journal of Child and Adolescent Psychopharmacology* 29:535–544
- 652 32. Sirugo G, Williams SM, Tishkoff SA (2019) The Missing Diversity in Human Genetic
653 Studies. *Cell* 177:26–31
- 654 33. Bentley AR, Callier S, Rotimi CN (2017) Diversity and inclusion in genomic research:
655 why the uneven progress? *Journal of Community Genetics* 8:255–266
- 656 34. Reichman NE, Teitler JO, Garfinkel I, McLanahan SS (2001) Fragile families: Sample
657 and design. *Children and Youth Services Review* 23:303–326
- 658 35. Ware EB, Fisher J, Schneper L, Notterman D, Mitchell C (2021) FFCWS polygenic
659 scores - release 1. Survey Research Center, Institute for Social Research, University of
660 Michigan; Department of Molecular Biology, Princeton University
- 661 36. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M
662 (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human
663 genome. *Epigenetics* 6:692–702
- 664 37. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD,
665 Irizarry RA (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis
666 of Infinium DNA methylation microarrays. *Bioinformatics* 30:1363–1369

- 667 38. Heiss JA, Just AC (2018) Identifying mislabeled and contaminated DNA methylation
668 microarray data: an extended quality control toolset with examples from GEO. *Clinical*
669 *Epigenetics*. <https://doi.org/10.1186/s13148-018-0504-1>
- 670 39. Chen Y, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, Gallinger S,
671 Hudson TJ, Weksberg R (2013) Discovery of cross-reactive probes and polymorphic CpGs in the
672 Illumina Infinium HumanMethylation450 microarray. *Epigenetics* 8:203–209
- 673 40. Middleton LYM, Dou J, Fisher J, et al (2021) Saliva cell type DNA methylation
674 reference panel for epidemiological studies in children. *Epigenetics* 1–17
- 675 41. McEwen LM, O’Donnell KJ, McGill MG, et al (2019) The PedBE clock accurately
676 estimates DNA methylation age in pediatric buccal cells. *Proceedings of the National Academy*
677 *of Sciences* 117:23329–23335
- 678 42. Lu AT, Quach A, Wilson JG, et al (2019) DNA methylation GrimAge strongly predicts
679 lifespan and healthspan. *Aging* 11:303–327
- 680

Fragile Families cohort
n=4898

Cohort with 450K methylation data
n=897 individuals with m=1806 samples

Methylation data QC: m=43 samples & n=36 individuals with with >10% of probes failing dropped,
m=18 samples & n=13 individuals with with discordant sex samples dropped,
m=3 samples & n=2 individuals with with abnormal sex chromosome intensity dropped &
m=4 samples & n=4 individuals with with contamination/mislabeled &
53 duplicate samples dropped

Cohort with quality controlled 450K data
n=882 individuals with m=1685 samples

Missing maternal data:
m=0 samples & n=0 individuals with with missing prenatal maternal smoking
m=4 samples & n=2 individuals with with missing prenatal alcohol
m=6 samples & n=3 individuals with with missing prenatal other drug use
m=0 samples & n=0 individuals with with missing maternal income to poverty ratio data
m=88 samples & n=47 individuals with with missing postnatal maternal smoking data
m=17 samples & n=17 individuals with with missing past month maternal/primary care giver smoking packs/day

m=1570 samples & n=828 individuals with maternal covariate data

Missing child data:
m=22 samples & n=13 individuals with with missing ancestry/genetic data
m=0 samples & n=0 individuals with with missing child sex data
m=0 samples & n=0 individuals with with missing child age at sample

m=1548 samples & n=815 individuals with child covariate data

n=759 individuals with a 9 year visit


n=789 individuals with a 15 year visit


n=6 individuals smoking
or missing child smoking data
at 9 year visit



n=43 individuals smoking
or missing focal child smoking data
at 15 year visit

Exclude children who smoke:
n=753 individuals with a 9 year visit

Exclude children who smoke:
n=746 individuals with a 15 year visit





A**B**